ArticleCancer2017
Clinicopathological features and clinical outcomes associated with TP53 and BRAF
Article in Cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 41 citations in OpenAlex.
- Exploration of the Potential Mechanisms of Yinqiao Powder in Treating Atopic Dermatitis: Integrating Network Pharmacology, Single-Cell, and Bulk RNA Sequencing.Journal of asthma and allergy · 2026Trial
- Efficacy and Safety of Trametinib in Non-V600 BRAF Mutant Melanoma: A Phase II Study.The oncologist · 2021Trial
- Older melanoma patients aged 75 and above retain responsiveness to anti-PD1 therapy: results of a retrospective single-institution cohort study.Cancer immunology, immunotherapy : CII · 2018Trial
- Somatic gene variation profiles in geriatric and adult malignant melanoma patients.Frontiers in oncology · 2025Article
- Follicular cell-derived thyroid carcinomas harboring novel geneticArchives of endocrinology and metabolism · 2024Article
- Evaluation of P53 immunostaining in patients with cutaneous melanoma.Biomedical reports · 2024Article
- Unique Spectrum of Activating BRAF Alterations in Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- Targeted Therapy for Melanomas Without BRAF V600 Mutations.Current treatment options in oncology · 2022Review
- Article
- The Genetics of Early-Stage Melanoma in a Veteran Population.Frontiers in oncology · 2022Article
- Review
- Management ofFrontiers in oncology · 2021Review
- Ultrasound-Mediated Microbubble Destruction Inhibits Skin Melanoma Growth by Affecting YAP1 Translation Using Ribosome Imprinting Sequencing.Frontiers in oncology · 2021Article
- Article
- Identification of key microRNAs of plasma extracellular vesicles and their diagnostic and prognostic significance in melanoma.Open medicine (Warsaw, Poland) · 2020Article
- Targeted Therapy in Advanced Melanoma With RareJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019Article
- Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing.BMC cancer · 2019Article
- Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients withClinical cancer research : an official journal of the American Association for Cancer Research · 2019Article
- Targeting the ERK Signaling Pathway in Melanoma.International journal of molecular sciences · 2019Review
- Natural Disease History, Outcomes, and Co-mutations in a Series of Patients With BRAF-Mutated Non-small-cell Lung Cancer.Clinical lung cancer · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundBRAF
methodsThis study analyzed the patient demographics, primary tumor features, and clinical outcomes of a large cohort of non-acral cutaneous melanoma patients who had undergone clinically indicated molecular testing (n = 926).
resultsThe prevalence of BRAF
conclusionsThese results add to the understanding of the clinical features associated with TP53 and BRAF
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.